CLR325
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
February 28, 2019
A Study of CLR325 in Chronic Stable Heart Failure Patients.
(clinicaltrials.gov)
- P2 | N=26 | Completed | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Completed | N=40 ➔ 26
Enrollment change • Trial completion • Cardiovascular • Heart Failure
September 20, 2016
A Study of CLR325 in Chronic Stable Heart Failure Patients.
(clinicaltrials.gov)
- P2 | N=16 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial primary completion date: Sep 2016 ➔ Apr 2017
Trial primary completion date • Cardiovascular • Heart Failure
April 11, 2017
A Study of CLR325 in Chronic Stable Heart Failure Patients.
(clinicaltrials.gov)
- P2 | N=16 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial primary completion date: Aug 2017 ➔ Sep 2018
Trial primary completion date • Cardiovascular • Heart Failure
August 21, 2017
A Study of CLR325 in Chronic Stable Heart Failure Patients.
(clinicaltrials.gov)
- P2 | N=40 | Recruiting | Sponsor: Novartis Pharmaceuticals | N=16 ➔ 40
Enrollment change • Cardiovascular • Heart Failure
March 02, 2016
A Study of CLR325 in Chronic Stable Heart Failure Patients.
(clinicaltrials.gov)
- P2 | N=16 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P2 trial • Cardiovascular • Heart Failure
June 10, 2016
A Study of CLR325 in Chronic Stable Heart Failure Patients.
(clinicaltrials.gov)
- P2 | N=16 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting | Initiation date: Feb 2016 ➔ May 2016
Enrollment open • Trial initiation date • Cardiovascular • Heart Failure
February 13, 2017
A Study of CLR325 in Chronic Stable Heart Failure Patients.
(clinicaltrials.gov)
- P2 | N=16 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial primary completion date: Apr 2017 ➔ Aug 2017
Trial primary completion date • Cardiovascular • Heart Failure
1 to 7
Of
7
Go to page
1